Showing results (31-40 of 89) with videos related to
Sort By:
Pageof 9
Annals of the Rheumatic Diseases|October 30, 2015
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trialGerd R Burmester, William F Rigby, Ronald F van Vollenhoven, et al.Rheumatology and Therapy|May 5, 2026
Golimumab for the Treatment of Rheumatoid Arthritis: A Narrative Review of Pivotal Randomized Trials and Real-World StudiesUta Kiltz, Yi-Ming Chen, Andrea Rubbert-Roth, et al.Annals of the Rheumatic Diseases|April 9, 2017
Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trialGerd R Burmester, William F Rigby, Ronald F van Vollenhoven, et al.The New England Journal of Medicine|October 14, 2020
Trial of Upadacitinib or Abatacept in Rheumatoid ArthritisAndrea Rubbert-Roth, Jeffrey Enejosa, Aileen L Pangan, et al.Rheumatology (Oxford, England)|January 29, 2021
Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritisDaniel Manoil, Delphine S Courvoisier, Benoit Gilbert, et al.RMD Open|July 26, 2024
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND studyRoy Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, et al.Rheumatology (Oxford, England)|June 23, 2026
Persistence and Effectiveness of upadacitinib and TNFi for rheumatoid arthritis using pooled data from Canadian and Swiss registriesDenis Choquette, Axel Finckh, Andrea Rubbert-Roth, et al.Rheumatology (Oxford, England)|September 20, 2011
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysisPaul Emery, Philip J Mease, Andrea Rubbert-Roth, et al.Annals of the Rheumatic Diseases|October 21, 2011
Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGEPaul P Tak, William Rigby, Andrea Rubbert-Roth, et al.Rheumatology and Therapy|April 29, 2024
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical TrialsGerd R Burmester, Jayne Stigler, Andrea Rubbert-Roth, et al.Pageof 9